Inhibition of miR301 enhances Akt-mediated cell proliferation by accumulation of PTEN in nucleus and its effects on cell-cycle regulatory proteins

Oncotarget

Volumn 7, Issue 15, 2016, Pages 20953-20965

  Jain, Mayur V ^a   Shareef, Ahmad ^a   Likus, Wirginia ^b   Cieślar Pobuda, Artur ^c   Ghavami, Saeid ^d   Łos, Marek J ^e,f  

^a LINKÖPING UNIVERSITY   (Sweden)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^d UNIVERSITY OF MANITOBA   (Canada)

^e POMERANIAN MEDICAL UNIVERSITY   (Poland)

^f LinkoCare Life Sciences AB   (Sweden)

Author keywords

AKT; MiR301; MTOR; PI3K; PTEN

Indexed keywords

CYCLIN B1; CYCLIN D1; MICRORNA; MICRORNA 301; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXF2; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; MIRN301 MICRORNA, HUMAN; PTEN PROTEIN, HUMAN; TUMOR MARKER;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; UPREGULATION; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; HUMANS; MICRORNAS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84964778154     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7996     Document Type: Article

References (47)

1. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends in molecular medicine. 2014; 20:460-469.
2. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer epidemiology, biomarkers & prevention. 2012; 21:1236-1243.
3. Song B, Wang C, Liu J, Wang X, Lv L, Wei L, Xie L, Zheng Y, Song X. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. Journal of experimental & clinical cancer research. 2010; 29:29.
4. Xu XH, Li DW, Feng H, Chen HM, Song YQ. MiR-300 regulate the malignancy of breast cancer by targeting p53. International journal of clinical and experimental medicine. 2015; 8:6957-6966.
5. Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, Wu Z, Chen T, Wu W, Lobie PE, Zhu T. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PloS one. 2012; 7:e41523.
6. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast cancer research. 2012; 14:R77.
7. Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, Shen CY. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast cancer research and treatment. 2012; 134:1081-1093.
8. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. International journal of cancer. 2007; 120:1046-1054.
9. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clinical cancer research. 2008; 14:419-427.
10. Ma X, Yan F, Deng Q, Li F, Lu Z, Liu M, Wang L, Conklin DJ, McCracken J, Srivastava S, Bhatnagar A, Li Y. Modulation of tumorigenesis by the pro-inflammatory microRNA miR-301a in mouse models of lung cancer and colorectal cancer. Cell Discovery. 2015; 1:15005.
11. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, McCready D, Fyles A, Liu FF. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer research. 2011; 71:2926-2937.
12. Gonsalves CS, Li C, Malik P, Tahara SM, Kalra VK. Peroxisome Proliferator alpha mediated transcription of miR-301a and miR-454 and their host gene SKA2 regulate Endothelin-1 and PAI-1 expression in sickle cell disease. Biosci Rep. 2015; 35. pii: e00275.
13. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nature reviews Molecular cell biology. 2010; 11:252-263.
14. Baker SJ. PTEN enters the nuclear age. Cell. 2007; 128:25-28.
15. Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A, Lucocq J, Downes CP. Localization of agonistsensitive PtdIns(3, 4, 5)P3 reveals a nuclear pool that is insensitive to PTEN expression. Journal of cell science. 2006; 119:5160-5168.
16. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature reviews Cancer. 2002; 2:489-501.
17. Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes & development. 2000; 14:1027-1047.
18. Altomare DA, Khaled AR. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Current medicinal chemistry. 2012; 19:3748-3762.
19. Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulinska-Litewka J, Basecke J, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget. 2014; 5:4603-4650. doi: 10.18632/oncotarget.2209.
20. Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, Fala F, Cocco L. Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cellular signalling. 2006; 18:1101-1107.
21. Jain MV, Jangamreddy JR, Grabarek J, Schweizer F, Klonisch T, Cieslar-Pobuda A, Los MJ. Nuclear localized Akt enhances breast cancer stem-like cells through counterregulation of p21(Waf1/Cip1) and p27(kip1). Cell cycle. 2015; 14:2109-2120.
22. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol. 2004; 15:177-182.
23. Jangamreddy JR, Jain MV, Hallbeck AL, Roberg K, Lotfi K, Los MJ. Glucose starvation-mediated inhibition of salinomycin induced autophagy amplifies cancer cell specific cell death. Oncotarget. 2015; 6:10134-10145. doi: 10.18632/oncotarget.3548.
24. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nature medicine. 2002; 8:1145-1152.
25. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nature reviews Genetics. 2009; 10:704-714.
26. Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006; 25:6220-6227.
27. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene. 2006; 25:6170-6175.
28. Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis. Cancer research. 2007; 67:4553-4555.
29. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005; 24:7455-7464.
30. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug resistance updates. 2002; 5:234-248.
31. Chaabane W, Cieslar-Pobuda A, El-Gazzah M, Jain MV, Rzeszowska-Wolny J, Rafat M, Stetefeld J, Ghavami S, Los MJ. Human-gyrovirus-Apoptin triggers mitochondrial death pathway-Nur77 is required for apoptosis triggering. Neoplasia. 2014; 16:679-693.
32. Jain MV, Paczulla AM, Klonisch T, Dimgba FN, Rao SB, Roberg K, Schweizer F, Lengerke C, Davoodpour P, Palicharla VR, Maddika S, Los M. Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. Journal of cellular and molecular medicine. 2013; 17:12-29.
33. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007; 128:129-139.
34. Lian Z, Di Cristofano A. Class reunion: PTEN joins the nuclear crew. Oncogene. 2005; 24:7394-7400.
35. Gerin I, Bommer GT, Lidell ME, Cederberg A, Enerback S, Macdougald OA. On the role of FOX transcription factors in adipocyte differentiation and insulin-stimulated glucose uptake. The Journal of biological chemistry. 2009; 284:10755-10763.
36. Ormestad M, Astorga J, Landgren H, Wang T, Johansson BR, Miura N, Carlsson P. Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development. 2006; 133:833-843.
37. Jonsson M, Dejmek J, Bendahl PO, Andersson T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer research. 2002; 62:409-416.
38. Fernandez-Cobo M, Zammarchi F, Mandeli J, Holland JF, Pogo BG. Expression of Wnt5A and Wnt10B in nonimmortalized breast cancer cells. Oncology reports. 2007; 17:903-907.
39. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature medicine. 2002; 8:1153-1160.
40. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Aktinduced phosphorylation in HER-2/neu-overexpressing cells. Nature cell biology. 2001; 3:245-252.
41. Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H. Subcellular localization of activated AKT in estrogen receptor-and progesterone receptor-expressing breast cancers: potential clinical implications. The American journal of pathology. 2010; 176:2139-2149.
42. Los M, Maddika S, Erb B, Schulze-Osthoff K. Switching Akt: from survival signaling to deadly response. BioEssays. 2009; 31:492-495.
43. Lee SR, Park JH, Park EK, Chung CH, Kang SS, Bang OS. Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. Journal of cellular physiology. 2005; 205:270-277.
44. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.
45. Ghavami S, Sharma P, Yeganeh B, Ojo OO, Jha A, Mutawe MM, Kashani HH, Los MJ, Klonisch T, Unruh H, Halayko AJ. Airway mesenchymal cell death by mevalonate cascade inhibition: integration of autophagy, unfolded protein response and apoptosis focusing on Bcl2 family proteins. Biochimica et biophysica acta. 2014; 1843:1259-1271.
46. Shakeri R, Hosseinkhani S, Los MJ, Davoodi J, Jain MV, Cieslar-Pobuda A, Rafat M, Ardestani SK. Role of the salt bridge between glutamate 546 and arginine 907 in preservation of autoinhibited form of Apaf-1. International journal of biological macromolecules. 2015; 81:370-374.
47. Cieslar-Pobuda A, Back M, Magnusson K, Jain MV, Rafat M, Ghavami S, Nilsson KP, Los MJ. Cell type related differences in staining with pentameric thiophene derivatives. Cytometry Part A. 2014; 85:628-635.